Overexpression of Rv3097c in Mycobacterium bovis BCG abolished the efficacy of BCG vaccine to protect against Mycobacterium tuberculosis infection in mice

Vaccine

Volumn 29, Issue 29-30, 2011, Pages 4754-4760

  Singh, Vipul K ^a   Srivastava, Vikas ^a   Singha, Vinayak ^a   Rastogi, Neeraj ^b   Roy, Raja ^b   Shaw, Arun K ^a   Dwivedi, Anil K ^a   Srivastava, Ranjana ^a   Srivastava, Brahm S ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

BCG; Lipase; Rv3097c; Triacylglycerol; Tuberculosis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; LIPASE Y; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; GENE OVEREXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; IMMUNE RESPONSE; IMMUNOGENICITY; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SURVIVAL; TH1 CELL; THIN LAYER CHROMATOGRAPHY;

EID: 79960619461     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.086     Document Type: Article

References (33)

1. WHO. Global tuberculosis control, surveillance, planning, financing; 2006.
2. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis Meta-analysis of the published literature. JAMA 1994;271:698-702.
3. Behr MA. BCG-different strains, different vaccines? Lancet Infect Dis 2002;2:86-92.
4. Dietrich G, Viret JF, Hess J. Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments. Vaccine 2003;21:667-70.
5. Daffe M, Draper P. The envelop layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol 1998;39:131-203.
6. Kremer L, de Chastellier C, Dobson G, Gibson KJC, Bifani P, Balor S, et al. Identification and structural characterization of an unusual mycobacterial monomeromycolyl-diacylglycerol. Mol Microbiol 2005;57:1113-26.
7. Camus J, Pryor M, Medigue C, Cole ST. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 2002;148:2967-73.
8. Guenin-Mace L, Simeone R, Demangel C. Lipids of pathogenic mycobacteria: contributions to virulence and host immune suppression. Transboundary Emerg Dis 2009;56:255-68.
9. Reed MB, Domenech P, Manca C, Su H, Barczak AK, Kreiswirth BN, et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 2004;431:84-7.
10. Stehr F, Kretschmar M, Kroger C, Hube B, Schafer W. Microbial lipases as virulence factors. J Mol Catal B: Enzym 2003;22:347-55.
11. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-44.
12. Deb C, Daniel J, Sirakova TD, Abomoelak B, Dubey VS, Kolattukudy PE. A novel lipase belonging to the hormone-sensitive lipase family induced under starvation to utilize stored triacylglycerol in Mycobacterium tuberculosis. J Biol Chem 2006;281:3866-75.
13. Mishra KC, Chastellier CD, Narayana Y, Bifani P, Brown AK, Bersa GS, et al. Functional role of the PE domain and immunogenicity of the Mycobacterium tuberculosis triacylglycerol hydrolase LipY. Infect Immun 2008;76:127-40.
14. Low KL, Srinivasa Rao PS, Shui G, Bendt AK, Pethe K, Dick T, et al. Triacylglycerol utilization is required for regrowth of in vitro hypoxic nonreplicating Mycobacterium bovis Bacillus Calmette-Guerin. J Bacteriol 2009;191:5037-43.
15. Srivastava V, Rouanet C, Srivastava R, Ramalingam B, Locht C, Srivastava BS. Macrophage-specific Mycobacterium tuberculosis genes: identification by green fluorescent protein and kanamycin resistance selection. Microbiology 2007;153:659-66.
16. Srivastava V, Jain A, Srivastava BS, Srivastava R. Selection of genes of Mycobacterium tuberculosis upregulated during residence in lungs of infected mice. Tuberculosis 2008;88:171-7.
17. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, et al. New use of BCG for recombinant vaccines. Nature 1991;351:456-60.
18. Parish T, Stoker NG. Electroporation of mycobacteria, Mycobacteria protocols. Methods in Molecular Biology 1998;101:129-44.
19. Gupta RK, Srivastava BS, Srivastava R. Comparative expression analysis of rpflike genes of Mycobacterium tuberculosis H37Rv under different physiological stress and growth conditions. Microbiology 2010;156:2714-22.
20. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucl Acid Res 2001;29:2002-7.
21. Akhtar P, Srivastava S, Srivastava A, Srivastava M, Srivastava BS, Srivastava R. Rv3303c of Mycobacterium tuberculosis protects tubercle bacilli against oxidative stress in vivo and contributes to virulence in mice. Microbes Infect 2006;8:2855-62.
22. Burguiere A, Hitchen PG, Dover LG, Kremmer L, Ridell M, Alexander DC, et al. Los A, a key glycosyl transferase involved in the biosynthesis of a novel family of glycosylated acyltrehalose lipooligosaccharides from Mycobacterium marinum. J Biol Chem 2005;280:42124-33.
23. Rosenkrands I, Agger EM, Olsen AW, Korsholm KS, Andersen CS, Jensen KT, et al. Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect Immun 2005;73:5817-26.
24. Prem Raj P, Srivastava S, Jain SK, Srivastava BS, Srivastava R. Protection by live Mycobacterium habana vaccine against Mycobacterium tuberculosis H37Rv challenge in mice. Indian J Med Res 2003;117:139-45.
25. Dunn PL, North RJ. Virulence ranking of some Mycobacterium tuberculosis and Mycobacterium bovis strains according to their ability to multiply in the lungs, induce lung pathology, and cause mortality in mice. Infect Immun 1995;63:3428-37.
26. Kaushal D, Schroeder BG, Tyagi S, Yoshimatsu T, Scott C, Ko C, et al. Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor SigH. Proc Natl Acad Sci USA 2002;99:8330-5.
27. Gunstone FD, Shukla VKS. NMR of lipids. In: Webb GA, Belton PS, McCarthy MJ, editors. Annual reports on NMR spectroscopy. London: Academic Press; 1995. p. 219-36.
28. Chen JM, Islam ST, Ren H, Liu J. Differential production of lipid virulence factors among BCG vaccine strains and implications on BCG safety. Vaccine 2007;25:8114-22.
29. Rollof J, Braconier JH, Soderstrom C, Nilsson-Ehle P. Interference of Staphylococcus aureus lipase with human granulocyte function. Eur J Clin Microbiol Infect Dis 1988;7:505-10.
30. Ryding U, Rennenberg J, Rollof J, Christensson B. Antibody response to Staphylococcus aureus whole cell, lipase and staphylolysin in patients with S. aureus infections. FEMS Microbial Immunol 1992;4:105-10.
31. Miskin JE, Farrell AM, Cunliffe WJ, Holland KT. Propionibacterium acnes, a resident of lipid-rich human skin, produces a 33 KDa extracellular lipase encoded by gehA. Microbiology 1997;143:1745-55.
32. Rollof J, Normark S. In vivo processing of Staphylococcus aureus lipase. J Bacteriol 1992;174:1844-7.
33. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007;23:2947-8.